Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 121

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 121
---
 ● | the countries in which the clinical trials are conducted; |

| ● | the length of time required to enroll eligible patients; |

| ● | the drop-out or discontinuation rates of patients; |

| ● | potential additional safety monitoring requested by regulatory agencies; |

| ● | the duration of patient participation in the clinical trials and follow-up; |

| ● | the phase of development of the product candidate; |

| ● | third party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; |

79

| ● | the cost of insurance, including product liability insurance, in connection with clinical trials; |

| ● | regulators or institutional review boards requiring that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; and |

| ● | the efficacy and safety profile of our product candidates. |

General and Administrative Expenses General and administrative expenses currently consist of consulting fees for the chief executive officer and professional fees for legal costs relating to our corporate matters, accounting and tax services and travel expenses. Other general and administrative expenses may also include professional fees for patents, insurance costs and board of directors’ expenses. We anticipate that our general and administrative expenses will increase in the future as we continue to support research and development activities and incur increased costs of operating a public company. These costs include increased headcount to support expanded operations and infrastructure, and the initiation, continuation and expansion of our preclinical studies and clinical trials for our product candidates. Additionally, we anticipate increased costs associated with maintaining compliance with Nasdaq rules and SEC requirements such as accounting, audit, legal and consulting services, as well as director and officer liability insurance, investor, and public relations activities. Results of Operations for the Three Months Ended March 31, 2025 and 2024 General and Administrative Expenses General and administrative expenses were $0.3 million for the three months ended March 31, 2025 as compared to $0.1 million for the three months ended March 31, 2024. The increase of $0.2 million was primarily related to increases in accounting and legal costs related to the Business Combination and general corporate matters during the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. Research and Development Expenses Research and development expenses were $0 for the three months ended March 31, 2025 as compared to $1